Prostate CA Clinical Trials

1,197 recruitingLast updated: June 9, 2026

There are 1,197 actively recruiting prostate ca clinical trials across 68 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include New York, New York, United States, Los Angeles, California, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Prostate CA Trials at a Glance

1,197 actively recruiting trials for prostate ca are listed on ClinicalTrialsFinder across 6 cities in 68 countries. The largest study group is Not Applicable with 349 trials, with the heaviest enrollment activity in New York, Los Angeles, and Houston. Lead sponsors running prostate ca studies include National Cancer Institute (NCI), Mayo Clinic, and Novartis Pharmaceuticals.

Treatments under study

About Prostate CA Clinical Trials

Looking for clinical trials for Prostate CA? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Prostate CA trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Prostate CA clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 1,197 trials

Recruiting
Not Applicable

Electric Cardiometry-Guided Standard Versus Restricted Fluid Therapy In Robotic Prostaectomy

SurgeryProstate CancerFluid Overload+1 more
Nazmy Edward Seif90 enrolled1 locationNCT07626151
Recruiting

Collection of Blood From Patients With Prostate Cancer

Prostate CancerMetastatic Prostate CancerCancer of Prostate+2 more
National Cancer Institute (NCI)1,000 enrolled1 locationNCT00923221
Recruiting

Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies

Breast CancerLiver CancerProstate Cancer+2 more
National Cancer Institute (NCI)750 enrolled1 locationNCT00451022
Recruiting
Phase 2

High Intensity Focused Ultrasound in Prostate Cancer

Prostate Cancer
University of Florida25 enrolled1 locationNCT06402357
Recruiting
Phase 1Phase 2

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Breast CancerOvarian CancerProstate Cancer+6 more
University of Florida29 enrolled1 locationNCT05000294
Recruiting
Phase 1

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Metastatic Hormone Sensitive Prostate CancerMetastatic Castration-resistant Prostate Neoplasms
Janssen Research & Development, LLC300 enrolled15 locationsNCT05818683
Recruiting
Phase 2

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate CarcinomaStage IV Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8+2 more
University of Utah33 enrolled1 locationNCT05168618
Recruiting

A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France

Prostatic NeoplasmsMetastatic Hormone Sensitive Prostate Cancer
Janssen Cilag S.A.S.270 enrolled1 locationNCT07451002
Recruiting
Phase 1

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Metastatic Castration-resistant Prostate Cancer (mCRPC)Small Cell Lung Cancer ( SCLC )Follicular Lymphoma ( FL)
Pfizer453 enrolled82 locationsNCT03460977
Recruiting
Phase 3

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

Prostate Cancer
Novartis Pharmaceuticals940 enrolled69 locationsNCT06855277
Recruiting
Phase 1Phase 2

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

Prostate Cancer
M.D. Anderson Cancer Center30 enrolled1 locationNCT06085729
Recruiting
Early Phase 1

Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients

Metastatic Prostate CarcinomaStage IV Prostate Cancer AJCC v8Localized Prostate Carcinoma+1 more
Mayo Clinic220 enrolled2 locationsNCT05045066
Recruiting
Phase 2

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

Prostate CancerProstate AdenocarcinomaProstatic Neoplasms
National Cancer Institute (NCI)42 enrolled1 locationNCT05616650
Recruiting
Phase 3

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Prostate CancerCancer of the ProstateHormone Sensitive Prostate Cancer+1 more
Pfizer1,000 enrolled331 locationsNCT07028853
Recruiting
Phase 1Phase 2

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Stage IVB Prostate Cancer AJCC v8Metastatic Malignant Neoplasm in the BoneMetastatic Castration-Resistant Prostate Carcinoma+1 more
National Cancer Institute (NCI)90 enrolled32 locationsNCT04071236
Recruiting
Not Applicable

Two-fraction HDR Monotherapy for Localized Prostate Cancer

Prostate AdenocarcinomaLocalized Prostate Carcinoma
University of California, San Francisco17 enrolled1 locationNCT05665738
Recruiting
Phase 3

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Metastatic Castration-resistant Prostate Cancer
Pfizer900 enrolled240 locationsNCT06629779
Recruiting

Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy

Prostate CancerProstatic Neoplasms
National Cancer Institute (NCI)300 enrolled1 locationNCT01834001
Recruiting
Phase 2

Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)

Metastatic Prostate Cancer
University Health Network, Toronto132 enrolled2 locationsNCT05404139
Recruiting
Phase 1Phase 2

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals205 enrolled9 locationsNCT07288359